NASDAQ:VTAE

(VTAE) (VTAE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$21.00
$21.00
50-Day Range
N/A
52-Week Range
$4.08
$21.03
Volume
N/A
Average Volume
763,870 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VTAE stock logo

About (VTAE) Stock (NASDAQ:VTAE)

Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

VTAE Stock News Headlines

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Vitae Pharmaceuticals Inc (VTAE)
See More Headlines
Receive VTAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (VTAE) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:VTAE
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

VTAE Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of (VTAE) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (VTAE) investors own include Bausch Health Companies (BHC), Mallinckrodt (MNK), Zosano Pharma (ZSAN), Akari Therapeutics (AKTX), Aquinox Pharmaceuticals (AQXP), Sangamo Therapeutics (SGMO), Trevena (TRVN) and Arbutus Biopharma (ABUS).

This page (NASDAQ:VTAE) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners